L M Fayad1, X Wang2, J O Blakeley3, D J Durand2, M A Jacobs4, S Demehri2, T K Subhawong5, T Soldatos6, P B Barker2. 1. From The Russell H. Morgan Department of Radiology and Radiological Science (L.M.F., X.W., D.J.D., S.D., M.A.J., P.B.B.)Orthopedic Surgery (L.M.F.)Oncology (L.M.F., M.A.J.), The Johns Hopkins Hospital Comprehensive Neurofibromatosis Center lfayad1@jhmi.edu. 2. From The Russell H. Morgan Department of Radiology and Radiological Science (L.M.F., X.W., D.J.D., S.D., M.A.J., P.B.B.). 3. Department of Neurology (J.O.B.), The Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. From The Russell H. Morgan Department of Radiology and Radiological Science (L.M.F., X.W., D.J.D., S.D., M.A.J., P.B.B.)Oncology (L.M.F., M.A.J.), The Johns Hopkins Hospital Comprehensive Neurofibromatosis Center. 5. Department of Radiology (T.K.S.), University of Miami Miller School of Medicine, Miami, Florida. 6. Research Unit of Radiology and Medical Imaging (T.S.), National and Capodestrian University of Athens, Evgenidion Hospital, Athens, Greece.
Abstract
BACKGROUND AND PURPOSE: The characterization of peripheral nerve sheath tumors is challenging. The purpose here was to investigate the diagnostic value of quantitative proton MR spectroscopy at 3T for the characterization of peripheral nerve sheath tumors as benign or malignant, compared with PET. MATERIALS AND METHODS: Twenty participants with 24 peripheral nerve sheath tumors underwent MR spectroscopy by use of a point-resolved sequence (TE, 135 ms). Six voxels were placed in 4 histologically proven malignant peripheral nerve sheath tumors and 22 voxels in 20 benign peripheral nerve sheath tumors (9 histologically proven, 11 with documented stability). The presence or absence of a trimethylamine signal was evaluated, the trimethylamine concentration estimated by use of phantom replacement methodology, and the trimethylamine fraction relative to Cr measured. MR spectroscopy results for benign and malignant peripheral nerve sheath tumors were compared by use of a Mann-Whitney test, and concordance or discordance with PET findings was recorded. RESULTS: In all malignant tumors and in 9 of 18 benign peripheral nerve sheath tumors, a trimethylamine peak was detected, offering the presence of trimethylamine as a sensitive (100%), but not specific (50%), marker of malignant disease. Trimethylamine concentrations (2.2 ± 2.8 vs 6.6 ± 5.8 institutional units; P < .049) and the trimethylamine fraction (27 ± 42 vs 88 ± 22%; P < .012) were lower in benign than malignant peripheral nerve sheath tumors. A trimethylamine fraction threshold of 50% resulted in 100% sensitivity (95% CI, 58.0%-100%) and 72.2% (95% CI, 59.5%-75%) specificity for distinguishing benign from malignant disease. MR spectroscopy and PET results were concordant in 12 of 16 cases, (2 false-positive results for MR spectroscopy and PET each). CONCLUSIONS: Quantitative measurement of trimethylamine concentration by use of MR spectroscopy is feasible in peripheral nerve sheath tumors and shows promise as a method for the differentiation of benign and malignant lesions. Trimethylamine presence within a peripheral nerve sheath tumor is a sensitive marker of malignant disease, but quantitative measurement of trimethylamine content is required to improve specificity.
BACKGROUND AND PURPOSE: The characterization of peripheral nerve sheath tumors is challenging. The purpose here was to investigate the diagnostic value of quantitative proton MR spectroscopy at 3T for the characterization of peripheral nerve sheath tumors as benign or malignant, compared with PET. MATERIALS AND METHODS: Twenty participants with 24 peripheral nerve sheath tumors underwent MR spectroscopy by use of a point-resolved sequence (TE, 135 ms). Six voxels were placed in 4 histologically proven malignant peripheral nerve sheath tumors and 22 voxels in 20 benign peripheral nerve sheath tumors (9 histologically proven, 11 with documented stability). The presence or absence of a trimethylamine signal was evaluated, the trimethylamine concentration estimated by use of phantom replacement methodology, and the trimethylamine fraction relative to Cr measured. MR spectroscopy results for benign and malignant peripheral nerve sheath tumors were compared by use of a Mann-Whitney test, and concordance or discordance with PET findings was recorded. RESULTS: In all malignant tumors and in 9 of 18 benign peripheral nerve sheath tumors, a trimethylamine peak was detected, offering the presence of trimethylamine as a sensitive (100%), but not specific (50%), marker of malignant disease. Trimethylamine concentrations (2.2 ± 2.8 vs 6.6 ± 5.8 institutional units; P < .049) and the trimethylamine fraction (27 ± 42 vs 88 ± 22%; P < .012) were lower in benign than malignant peripheral nerve sheath tumors. A trimethylamine fraction threshold of 50% resulted in 100% sensitivity (95% CI, 58.0%-100%) and 72.2% (95% CI, 59.5%-75%) specificity for distinguishing benign from malignant disease. MR spectroscopy and PET results were concordant in 12 of 16 cases, (2 false-positive results for MR spectroscopy and PET each). CONCLUSIONS: Quantitative measurement of trimethylamine concentration by use of MR spectroscopy is feasible in peripheral nerve sheath tumors and shows promise as a method for the differentiation of benign and malignant lesions. Trimethylamine presence within a peripheral nerve sheath tumor is a sensitive marker of malignant disease, but quantitative measurement of trimethylamine content is required to improve specificity.
Authors: Eline Beert; Hilde Brems; Bruno Daniëls; Ivo De Wever; Frank Van Calenbergh; Joseph Schoenaers; Maria Debiec-Rychter; Olivier Gevaert; Thomas De Raedt; Annick Van Den Bruel; Thomy de Ravel; Karen Cichowski; Lan Kluwe; Victor Mautner; Raf Sciot; Eric Legius Journal: Genes Chromosomes Cancer Date: 2011-08-24 Impact factor: 5.006
Authors: Laura M Fayad; Nouha Salibi; Xin Wang; Antonio J Machado; Michael A Jacobs; David A Bluemke; Peter B Barker Journal: AJR Am J Roentgenol Date: 2010-01 Impact factor: 3.959
Authors: Ty K Subhawong; Xin Wang; Daniel J Durand; Michael A Jacobs; John A Carrino; Antonio J Machado; Laura M Fayad Journal: AJR Am J Roentgenol Date: 2012-01 Impact factor: 3.959
Authors: Laura M Fayad; David A Bluemke; Edward F McCarthy; Kristin L Weber; Peter B Barker; Michael A Jacobs Journal: J Magn Reson Imaging Date: 2006-01 Impact factor: 4.813
Authors: Stephen M Broski; Geoffrey B Johnson; Benjamin M Howe; Mark A Nathan; Doris E Wenger; Robert J Spinner; Kimberly K Amrami Journal: Skeletal Radiol Date: 2016-04-26 Impact factor: 2.199
Authors: Julian Zipfel; Meizer Al-Hariri; Isabel Gugel; Karin Haas-Lude; Alexander Grimm; Steven Warmann; Michael Krimmel; Victor-Felix Mautner; Marcos Tatagiba; Martin U Schuhmann Journal: Childs Nerv Syst Date: 2020-06-06 Impact factor: 1.475
Authors: Roy A Raad; Shailee Lala; Jeffrey C Allen; James Babb; Carole Wind Mitchell; Ana M Franceschi; Kaleb Yohay; Kent P Friedman Journal: World J Nucl Med Date: 2018 Oct-Dec
Authors: Enrico Martin; Ritchie T J Geitenbeek; J Henk Coert; David F Hanff; Laura H Graven; Dirk J Grünhagen; Cornelis Verhoef; Walter Taal Journal: Neuro Oncol Date: 2021-04-12 Impact factor: 12.300